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Abstract 
Professor Nagtegaal had already highlighted that lymph nodes were probably not 
responsible for the development of liver metastases. If they are not, then is there 
another mechanism? Professor Haboubi addresses the question of extranodal 
deposits – their frequency and their importance in the development of metastatic 
disease. The experts review the evidence and discuss whether this information will 
alter treatment decisions and staging systems in future. 
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To answer the question whether Extra Nodal Tumour Deposits (ENDs) and the Extra 
Mural Vascular Invasion (EMVI) should be treated the same, the following questions 
have to be answered: are they readily recognisable, are they related and can we 
delineate prognostics?  
 
There is some confusion in the literature. The first area of confusion is the definition 
of ENDs, also known as tumour deposits (TD) which have been defined as 
"microscopic mesorectal or mesocolic soft tissue extranodal deposits which are 
discontinuous with the primary tumour [1]. There are contradictions in terms of the 
use of the words microscopic and also discontinuous as will be seen later.  
 
Recognition and nature 
There is disagreement in the literature about how often ENDs are demonstrated. 
Wang et al say they see ENDs in all cases of rectal cancer when they use the large 
slide mount [2]. But most authors don't see them that often and they are reported 
anywhere between 4.5-45% of rectal cancers and 17.6-25.5% of colon cancers.  
 
What is the route of deposition i.e. how do ENDs breach the bowel wall? Is it through 
the vascular, perineural or lymphatic permeation, or indeed as direct deposits? The 
latter route exemplifies the first element of confusion, as according to the original 
description the deposits should be discontinuous 
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The critical paper from Nagtegaal et al speculates that the "origin of EMDs can be 
heterogeneous as they may represent true lymph node replacement"[3], which is 
again a contradiction to the original definition as an extra-nodular disease. They also 
speculated that they could be "vascular, lymphatic or perineural space invasion and 
often a combination of patterns"[3]. It is therefore difficult to delineate the prognostics 
in this particular area. There is however general agreement that ENDs are bad  
independent prognostic indicator with a hazard ratio for death from the disease at 
1.96[3]. 
 
However there is a further challenge. The Duke's classification did not identify 
tumour deposits as a separate entity; they may have been thought to represent 
lymph nodes. This pattern may have been replicated where in old series of lymph 
node retrievals little deposits in the fat may have been regarded to be lymph nodes! 
 
Overall the TNM position with regards to tumour deposits is bizarre. Initially TNM 5th 
edition definition depended on the size. If the nodule was ≤3 mm it was regarded as 
a tumour deposit, if >3mm it was regarded as a lymph node, and therefore pN1. 
TNM version 6 recognised the contour and not the size. So that if the nodule is round 
- it should be considered as lymph node, if it is not round it is not a lymph node but a 
tumour deposit (and could represent venous invasion), which is either microscopic 
(V1) or macroscopically evident (V2). Yet again the macroscopic recognition of such 
lesions automatically contradicted the original definition of ENDs! TNM version 7 
recognises ENDs as N1c.  
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Tumour deposits and lymph node status 
In the published literature tumour deposits are seen in approximately one third to 
almost two thirds of lymph node negative cases. However there is always an 
agreement of bad prognosis irrespective of the stage of the disease. 
 
Puppa et al proposed a more comprehensive classification approach in terms of the 
shape and involvement of other structures and described the prognostic implications 
of the 3 morphological variants namely vascular (lymphatic or venous), ENDs other 
than vascular or peri neural and thirdly EMVI and peri neural invasion type ENDs:  
They suggested that the presence of tumour deposits within the lymphatic or 
vascular space (i.e. T staging) is associated with an overall survival HR of 2.5. 
Tumour deposits of the non vascular invasion type are associated with poorer 
prognosis (HR 4.7, similar to lymph node metastases) and finally deposits with 
extramural venous and perineural invasion have the poorest prognosis [HR 8][4].   
This paper highlights the various histological features and gives some prognostic 
indicators related to the pattern, however this does need to be validated.  
 
Prebhudesai  et al  looked at 55 patients with Duke's B and C rectal cancer - 29 
patients had ENDs (8 Duke's B) and 26 controls and showed that the presence of 
tumour deposits was associated with earlier distant metastases (14 months vs 37 
months, p=0.001). There were significant increases in the incidence of liver 
metastasis (31.03% vs 11.5%, p=0.08), local recurrence (17.8% vs 3.8%, p=ns) and 
poorer 3 year mortality (16 vs 7 patients, p=0.09).  The authors also showed there 
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was also an association with EMVI (p=0.017), perineural invasion (p=0.039) and 
lymph node involvement (p=0.008)[5].  
 
Extramural venous invasion 
There are problems with the recognition of EMVI and therefore problem with regards 
prognosis mostly due to the fact that pathologists vary in recognising EMVI. If we 
analyse synoptic reporting there are some pathologists who are very good in 
registering EMVI but if you showed the same slide to various pathologists you would 
get different readings and this is a problem.  
 
Prof I. Nagtegaal showed that pathologists identify vascular invasion in about half of 
cases but in UK this figure varies significantly. In 1980 Talbot et al showed the same 
results. He also reported that intramural vascular invasion is important but not as 
important much as extramural vascular invasion and showed elegantly that these 
features are related to the lymph node metastasis, Duke’s staging, liver metastasis 
and survival[6].  
 
A more recent paper from the Concord Group in Sydney with 3040 patients reported 
that prognosis is stage specific and that both mural and extramural vascular invasion 
are independent predictors for poor prognosis, but only in Stage C disease (as 
classified by the ACP staging, Stage III)[7]. 
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A recent paper by Chand et al gave, on evidence base, recommendations for 
radiological and histopathological reporting of EMVI. The authors emphasised what 
has been known that elastic tissue stains increase the yield of EMVI recognition.  
This may be difficult to implement given the variations in capabilities of the 
departments, but the use of specialised stained may reduce the variables for the 
recognition of EMVI. The authors also conclude that radiology (MRI) is at least as 
sensitive as histology in identifying EMVI, and has the benefit of being more dynamic 
and repeatable. MDTs need to keep auditing EMVI detection rates by both 
disciplines[8].  
 
So to answer the question whether ENDs and EMVI should be treated the same, I 
would say probably yes, because some are interrelated, they are independently 
associated with lymph node metastases, poor survival and advanced staging. 
 
Discussion 
Dr M. Morgan:  In terms of examining the pathological specimen it's really about 
   good sampling, so looking for those extra nodal deposits. I’m not 
   sure that as pathologists we are very good at picking [them] up. 
   We don’t examine all of the tumour all of the time. 
 
Prof B. Heald: It seems to me that Prof G. Brown's paper and observations that 
   the greatest prognostic indicator before surgery is the response 
   to chemotherapy and radiotherapy [are important]. I’m not sure 
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   whether it’s the response to chemotherapy alone, that would be 
   a good thing, but surely all our planning has to be dominated by 
   a sequence of MRI followed by treatment followed by MRI, and 
   at some point we have to decide which way we are going for  
   responders or non-responders. 
 
Prof D. Cunningham: I have an impression that we are over treating significant  
   numbers of patients with rectal cancer. It is a spectrum, there 
   are patients who have excellent prognosis with very early  
   disease who just need a good operation and then there are  
   some people with more advanced disease where you can use 
   either chemotherapy or chemoradiotherapy as a means of  
   determining biology/response and therefore outcome. I am  
   assuming you are addressing that to the higher risk patients. 
   What do the panel feel about using response to chemotherapy 
   in higher risk patients as a way of evaluating outcome and  
   biology.  
 
Dr C. Fernandez Martinez: I think it is very important in the next generation of clinical 
   trials to try to introduce patients in our trials with really high risk 
   of relapse. MRI is a good tool to know which patients are high 
   risk. Extramural venous invasion is probably the most important 
   predictive factor for metastatic disease and CRM [positivity]. We 
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   must introduce this kind of information in order to treat the  
   right patients in the next generation of clinical trials.  
 
Prof C. Eng:   I understand what you’re saying if we are specifically talking  
   about rectal cancer but it doesn’t apply to all cancers. All the  
   trials that have looks at pathCR have varied everywhere from 
   5% to 35% but that does not result in increased overall survival. 
   I just want to make sure that we keep in mind that although you 
   have a great response upfront in terms of path CR that that may 
   not help down the [line] and there may be more of a sequencing 
   issue there.  
 
Prof D. Cunningham: Can I come back to EMVI, which is one of the conversations in 
   our MDT in relation to rectal cancer. Is EMVI more important  
   than anything else and should it be the primary determinant of 
   how we manage patients in terms of upfront chemotherapy and 
   post-operative chemotherapy? This is one of the challenges that 
   I face as an oncologist, we know that actually adjuvant  
   chemotherapy is of some benefit in these patients, the  
   incremental gain is not that great but should we use EMVI as the 
   driver for [treatment]?   
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Dr P. Nilsson: I don’t know the answer to that but I think that it is complicated 
   because in rectal cancer we have two almost equally important 
   endpoints, local and systemic control, and it depends on what 
   you are aiming for. You want to get good results for both. EMVI 
   might be important for systemic control but does it have any  
   effect on local control? 
 
Dr C. Fernandes-Martinez: Systemic relapse is important in high-risk rectal cancer. 
   Surgeons have very little local relapse but systemic relapse is 
   more of an issue (30% in 5 years). Chemotherapy as optimum 
   systematic treatment must be applied. To move forward the  
   induction strategy is a good idea. [It is] also [important] to know 
   which [patients] need radiotherapy or just need chemotherapy. 
   Those with EMVI positivity  are probably best treated with just 
   chemotherapy rather than chemoradiation as local relapse [rates 
   are] very low. 
 
Audience:   When do you think it is best operating after    
   chemoradiation and what do you think the mechanisms for  
   better outcome are if we operate later, because it seems  
   counterintuitive leaving the tumour in place for longer and then 
   taking it out, assuming that you're getting the same operation. 
   Why is it that you get better survival by taking it out late?  In  
   addition the new trials of neoadjuvant chemotherapy don’t have 
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   the radiotherapy component e.g. BACCHUS, are there any  
   reservations on leaving out radiotherapy? 
 
Prof D. Cunningham: What is the best time [to operate]? Is it at the standard time, 
   which is 4-6 weeks, or should we wait longer? What are the  
   gains and what could we lose?  
 
Dr P. Nilsson:  I get the impression that we are learning to wait longer and  
   longer, how long we should wait and what is optimal is yet to be 
   found out.  
 
Dr A. Mirzenami:  The difficulty is that tumours are very heterogeneous and their 
   response to treatment is also extremely heterogeneous. So it is 
   very difficult to have standardisation on how long we leave it for 
   different patients. 
 
Prof G. Brown:  Just a point on pelvic recurrence in patients with EMVI. The  
   problem we have is that most patients with EMVI do have  
   characteristically classically defined advanced disease, and  
   even in some of these trials they’re probably not the ones that 
   are being treated with primary chemotherapy. There are a few 
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   studies but [they haven't recruited patients with very] advanced 
   EMVI.  
 
   If you look at the ACCORD data there is a relationship between 
   the risk of EMVI positivity and CRM positivity. They’re linked and 
   the reason for this is probably that once the tumour has got into 
   the vessel the vessel itself does not respect the mesorectal  
   envelope or boundaries, unlike lymph nodes which confine  
   themselves to within the mesorectum, there is therefore a  
   mechanism for lateral spread to the pelvic sidewall   
   compartments. So the other piece of evidence about avoiding 
   radiotherapy in EMVI positive patients is the strong positive link 
   between pelvic sidewall nodal metastases and EMVI that we 
   may be masking by the use of radiotherapy. These patients do 
   not relapse with pelvic lymph node recurrence because of the 
   protective effect of the radiotherapy. So we have to be careful 
   that this late development after treatment may only emerge and 
   will be masked by the path CR rates.  
 
Prof J. Nicholls: This is a question to the pathologists. Could the failure to find 
   lymph node deposits be technical? It would be interesting to  
   hear, given the size of tumour cells and indeed the thickness of 
   sections taken, the view of the pathologist as to whether [it  
   would be worth looking further for these deposits] where we  
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   could be finding very small metastatic disease which is [actually] 
   biologically insignificant.  
 
Dr M. Morgan:  In terms of looking for lymph nodes the biggest problem I get is 
   that we haven’t found 12 lymph nodes and clearly it is an  
   important question. We look hard for them using [multiple  
   methods]. There is some evidence that the more you look you 
   don't find [more positive] nodes. Unlike in breast cancer we are 
   not looking very hard for microscopic deposits, this would mean 
   a lot of extra work.  
 
Concept 2: TNM staging  
Prof G. Brown:  One more comment from Prof M. Mason about TNM, from what 
   [you've] heard this morning do you think the TNM classification 
   needs modification?  
 
Prof M. Mason:  Under the current c TNM-7 classification the distinction between 
   N1a and N1c is subjective and unreliable. The reason [we  
   haven't changed it] is because we have not yet heard articulated 
   a convincing argument that it really matters. Through the whole 
   TNM classification [there are] areas where things are subjective 
   and unverified. What I particularly want to hear is the voice of 
   the oncologists, I want to know whether there is evidence that 
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   for a [single] patient, the distinction between N1a and N1c as the 
   sole determinant makes a real difference to a treatment  
   decision. The clinical opinion we currently have [says it's] not a 
   perfect classification but that it does not matter than much from 
   the point of view of making major treatment decisions.   
 
Dr M. Morgan:  Following on from what Professor Malcolm Mason has just said, 
   the second objective was “Do we need to overcome the  
   shortcomings of a TNM system? Do we recognize that there are 
   problems with it? And if so, what do need to do about it? How do 
   we make that better? How do we propose improvement in  
   TNM?” 
 
Prof D. Cunningham: Also if some of our oncologists could comment on whether  
   there is a real difference between an N1a and N1c and how that 
   might influence what they do.  
 
Prof M. Berho:   The TNM system is not [perfect] but it has very good parts and 
   we need to acknowledge that. Actually, the anatomical extent of 
   the disease is very important for the oncologist to make  
   treatment decisions so to just dismiss it is probably   
   inappropriate. The TNM committee has recognized the flaws of 
   the system and it is continuously trying to enhance it, in the last 
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   edition, several other factors besides the classic pT and pN  
   [stage] are mentioned, including certain critical molecular  
   markers that influence prognosis and treatment, such as MSI 
   status and KRAS mutation analysis. 
 
   Although it is very possible that the mechanism of distant  
   metastasis is, in some cases, independent of lymph node  
   metastasis, it is also important to point out that not all lymph  
   node metastasis are recognized, either due to  an inadequate 
   number of lymph nodes examined, as well as the presence of 
   metastatic disease that requires of ancillary techniques to be 
   identified. It has been shown that micro metastases are  
   associated with a more clinical aggressive outcome. 
 
Audience:  I am a surgeon, from my point of view, it´s a big   
   problem if you continuously modify small bits and pieces where 
   there is no evidence that it is reliable and that it matters. [This is 
   a problem for] long term prospective registries. 
 
Audience:   [It is] important that we change therapies based on evidence; 
   on clinical trials, randomized trials, high levels of evidence. But 
   [over the last 15 years we have been] changing TNM [without 
   an] evidence-[base]. [This is a problem because as] you change 
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   staging, you change [which] people are treated treatments you 
   have tested for other stages. 
 
Prof M. Mason:  Absolutely you do not want to change TNM unless there is  
   evidence behind it.  
 
Dr M. Morgan:  We are not going to get the evidence while we are all doing  
   different things.  
 
Audience:   I fully agree. I use TNM everyday in my clinic so that´s very  
   useful and I´m against changing that, but me the important issue 
   is that TNM is based upon the consequences of the disease. 
   There is nothing we can modify. So it is a very anatomic concept 
   and we need to incorporate new knowledge into that by  
   incorporating those pathogenetic mechanisms that are  
   important.  
 
   I would therefore like to better understand the development of 
   metastatic disease and then to incorporate those factors into 
   clinical decision [making]. 
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Summary of the key points  
 The pathological identification of extra nodal deposits is challenging and relies 
on good sampling. Elastin stains enhances such recognition. 
 ENDs are bad independent prognostic indictors and may be secondary to 
“vascular, lymphatic or perineural space invasion and often a combination of 
patterns”[3]. 
 Tumour deposits are seen in approximately one third to two thirds of lymph 
node negative cases.  
 Tumour deposits with extramural venous and perineural invasion have the 
poorest prognosis.  
 MRI is at least as sensitive as histology in identifying EMVI, and has the 
benefit of being more dynamic and repeatable. MDTs need to keep auditing 
EMVI detection rates by both disciplines 
 ENDs and EMVI should be treated similarly. They are independently 
associated with lymph node metastases, poor survival and advanced staging.  
 It is possible that EMVI may be a better primary driver for the use of systemic 
treatment.  
 Systemic relapse is a greater issue than local control, induction treatment 
could be considered, and it will be important to know whether patients need 
chemotherapy, radiotherapy or both.  
 EMVI may be best treated with chemotherapy rather than chemoradiotherapy 
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as local relapse rates are low.  However EMVI positivity and CRM positivity 
are linked and EMVI positivity is associated with lateral spread into the pelvic 
side wall. The current use of radiotherapy to treat patients EMVI may be 
obscuring the true prevalence of pelvic side wall metastases.  
 The distinction between N1a and N1c disease in TNM-7 is subjective and 
unreliable but in order to change it studies are required to show this distinction 
is a sole determinant for treatment decisions.  
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Audience voting  
Question: Extranodal tumour deposits are a high-risk feature associated with EMVI  
 Strongly agree: 41% 
 Agree: 43% 
 Neutral: 11% 
 Disagree: 3% 
 Strongly disagree: 2% 
 
Question: Extranodal tumour deposits should be documented 
 Strongly agree: 60% 
 Agree: 35% 
 Neutral: 2% 
 Disagree: 1% 
 Strongly disagree: 2% 
 
Question: Is it worth considering EMVI as a driver for adjuvant therapy decisions.  
 Strongly agree: 30% 
 Agree: 47% 
 Neutral: 11% 
 Disagree: 2% 
 Strongly disagree: 1% 
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